AMENDMENTS TO THE CLAIMS

1-28. **(Canceled)**

29. **(Currently Amended)** A method for ameliorating the effects of chronic inflammation in a subject which comprises administering ~~one or more antibodies selected from the group~~

~~consisting of:~~

~~(i) an antibody specific for M-CSF~~

~~(ii)~~ an antibody specific for GM-CSF to the subject~~, and~~

~~(iii) a combination of (i) and (ii),~~

for a time and in an amount to inhibit or otherwise antagonize the effects of ~~M-CSF or~~ GM-CSF on cells of the monocyte~~/~~ or macrophage lineage.

30. **(Currently Amended)** The method of Claim 29, wherein inhibiting or otherwise antagonizing the effects of ~~M-CSF,~~ GM-CSF ~~or both~~ on cells of the monocyte~~/~~ or macrophage lineage comprises reducing the level of proliferation, activation, growth and/or survival or cells of the monocyte~~/~~ or macrophage lineage.

31. **(Currently Amended)** The method of Claim 29 or 30, wherein said antibody ~~antibodies antagonize~~ antagonizes the effect of ~~M-CSF,~~ GM-CSF ~~or both~~.

32. **(Previously Presented)** The method of Claim 29 or 30, wherein the antibody is ~~antibodies are~~ identified through natural product screening or screening of a chemical library.

33. **(Currently Amended)** The method of Claim 29 ~~31~~, wherein the antibody is ~~antibodies are~~ internalized by the monocyte~~/~~ or macrophage cells.

34. **(New)** The method of claim 29, wherein said administered antibody inhibits or otherwise antagonizes the effects of GM-CSF on cells of the monocyte lineage.

35. **(Canceled)**

36. **(New)** The method of claim 29, wherein said antibody is a monoclonal antibody.

37. **(New)** The method of claim 29, wherein said administered antibody inhibits or otherwise antagonizes the effects of GM-CSF on cells of the macrophage lineage.

38. **(New)** The method of claim 29, wherein said subject is a human.

39. **(New)** The method of claim 29, wherein said administered antibody inhibits or otherwise antagonizes the effects of GM-CSF on macrophage cells.

40. **(New)** The method of claim 29, wherein said antibody is administered intravenously.

41. **(New)** The method of claim 29, wherein said antibody is administered subcutaneously.

42. **(New)** The method of claim 29, wherein the inflammation is a chronic inflammation selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease, Crohns disease, type I diabetes, multiple sclerosis, chronic inflammatory lung disease and psoriasis.

43. **(New)** The method of claim 41, wherein the inflammation is a chronic inflammatory lung disease selected from the group consisting of asthma, chronic bronchitis, emphysema and chronic obstructive airway disease.

44. **(New)** The method of claim 36, wherein said antibody is administered prophylactically.

45. **(New)** The method of claim 29, further comprising co-administering to the subject one or more other compounds or molecules designed to reduce or alleviate any one or more symptoms of an inflammatory response.

46. **(New)** The method of claim 45, wherein said one or more other compounds or molecules is administered simultaneously with said antibody specific for GM-CSF.

47. **(New)** The method of claim 45, wherein said one or more other compounds or molecules is administered sequentially compared to said antibody specific for GM-CSF.

48. **(New)** A method for ameliorating the effects of inflammation in a subject exhibiting inflammation, which comprises administering to said subject exhibiting inflammation an antibody specific for GM-CSF for a time and in an amount to inhibit or otherwise antagonize the effects of GM-CSF on cells of the monocyte or macrophage lineage.

49. **(New)** The method of Claim 48, wherein inhibiting or otherwise antagonizing the effects of GM-CSF on cells of the monocyte or macrophage lineage comprises reducing the level of proliferation, activation, growth and/or survival or cells of the monocyte or macrophage lineage.

50. **(New)** The method of Claim 48, wherein said antibody antagonizes the effect of GM-CSF.

51. **(New)** The method of Claim 48, wherein the antibody is internalized by the monocyte or macrophage cells.

52. **(New)** The method of claim 48, wherein said administered antibody inhibits or otherwise antagonizes the effects of GM-CSF on cells of the monocyte lineage.

53. **(New)** The method of claim 48, wherein said antibody is a monoclonal antibody.

54. **(New)** The method of claim 48, wherein said administered antibody inhibits or otherwise antagonizes the effects of GM-CSF on cells of the macrophage lineage.

55. **(New)** The method of claim 48, wherein said subject is a human.

56. **(New)** The method of claim 48, wherein said administered antibody inhibits or otherwise antagonizes the effects of GM-CSF on macrophage cells.

57. **(New)** The method of claim 48, wherein said antibody is administered intravenously.

58. **(New)** The method of claim 48, wherein said antibody is administered subcutaneously.

59. **(New)** The method of claim 49, wherein the inflammation is a chronic inflammation selected from the group consisting of rheumatoid arthritis, inflammatory bowel disease, Crohns disease, type I diabetes, multiple sclerosis, chronic inflammatory lung disease and psoriasis.

60. **(New)** The method of claim 59, wherein the inflammation is a chronic inflammatory lung disease selected from the group consisting of asthma, chronic bronchitis, emphysema and chronic obstructive airway disease.

61. **(New)** The method of claim 48, further comprising co-administering to the subject one or more other compounds or molecules designed to reduce or alleviate any one or more symptoms of an inflammatory response.

62. **(New)** The method of claim 61, wherein said one or more other compounds or molecules is administered simultaneously with said antibody specific for GM-CSF.

63. **(New)** The method of claim 61, wherein said one or more other compounds or molecules is administered sequentially compared to said antibody specific for GM-CSF.

64. **(New)** A method for ameliorating the effects of chronic inflammation in a subject in need of treatment for said chronic inflammation which comprises administering an antibody

specific for GM-CSF to said subject for a time and in an amount to inhibit or otherwise antagonize the effects of GM-CSF on macrophage cells of the subject.

SUMMARY OF INTERVIEW

Attendees, Date and Type of Interview

The interview with Examiner Belyavskyi was conducted in-person at the USPTO on June 15, 2007, and attended by the undersigned attorney along with the inventor Gary Anderson, and another attorney.

Exhibits and/or Demonstrations

No exhibits or demonstrations were presented.

Identification of Claims Discussed

All claims of record were discussed.

Identification of Prior Art Discussed

A selection of the prior art submitted in the Information Disclosure Statement accompanying the present Amendment was discussed.

Proposed Amendments

An amendment to the claims limiting them to the use of an antibody specific for GM-CSF was discussed.

Principal Arguments and Other Matters

It was argued that the proposed amendment to the claims would overcome the interference issues.

Results of Interview

The Examiner agreed that limiting the claims as proposed would overcome the interference issues. The Examiner also indicated that Applicants should submit a Declaration in order to further evidence the patentability of the amended claims over the prior art submitted in the accompanying Information Disclosure Statement.